Cell Reports Methods,
Journal Year:
2023,
Volume and Issue:
3(2), P. 100411 - 100411
Published: Feb. 1, 2023
Combination
therapy
is
a
promising
approach
in
treating
multiple
complex
diseases.
However,
the
large
search
space
of
available
drug
combinations
exacerbates
challenge
for
experimental
screening.
To
predict
synergistic
different
cancer
cell
lines,
we
propose
an
improved
deep
forest-based
method,
ForSyn,
and
design
two
forest
types
embedded
ForSyn.
ForSyn
handles
imbalanced
high-dimensional
data
medium-/small-scale
datasets,
which
are
inherent
characteristics
combination
datasets.
Compared
with
12
state-of-the-art
methods,
ranks
first
on
four
metrics
eight
datasets
feature
combinations.
We
conduct
systematic
analysis
to
identify
most
appropriate
configuration
parameters.
validate
predictive
value
cell-based
experiments
several
previously
unexplored
Finally,
importance
performed
top
contributing
features
extracted
by
The
resulting
key
genes
may
play
roles
corresponding
cancers.
Signal Transduction and Targeted Therapy,
Journal Year:
2023,
Volume and Issue:
8(1)
Published: Nov. 3, 2023
Abstract
Smart
nanoparticles,
which
can
respond
to
biological
cues
or
be
guided
by
them,
are
emerging
as
a
promising
drug
delivery
platform
for
precise
cancer
treatment.
The
field
of
oncology,
nanotechnology,
and
biomedicine
has
witnessed
rapid
progress,
leading
innovative
developments
in
smart
nanoparticles
safer
more
effective
therapy.
In
this
review,
we
will
highlight
recent
advancements
including
polymeric
dendrimers,
micelles,
liposomes,
protein
cell
membrane
mesoporous
silica
gold
iron
oxide
quantum
dots,
carbon
nanotubes,
black
phosphorus,
MOF
others.
We
focus
on
their
classification,
structures,
synthesis,
intelligent
features.
These
possess
the
ability
various
external
internal
stimuli,
such
enzymes,
pH,
temperature,
optics,
magnetism,
making
them
systems.
Additionally,
review
explore
latest
studies
tumor
targeting
functionalizing
surfaces
with
tumor-specific
ligands
like
antibodies,
peptides,
transferrin,
folic
acid.
also
summarize
different
types
options,
small
molecules,
proteins,
nucleic
acids,
even
living
cells,
potential
use
While
is
promising,
acknowledge
challenges
clinical
prospects
associated
use.
Finally,
propose
blueprint
that
involves
artificial
intelligence-powered
treatment
applications.
By
harnessing
aims
usher
new
era
personalized
therapy,
providing
patients
individualized
options.
Science Translational Medicine,
Journal Year:
2023,
Volume and Issue:
15(706)
Published: July 26, 2023
Organoid
models
have
the
potential
to
recapitulate
biological
and
pharmacotypic
features
of
parental
tumors.
Nevertheless,
integrative
pharmaco-proteogenomics
analysis
for
drug
response
biomarker
investigation
precision
therapy
patients
with
liver
cancer
are
still
lacking.
We
established
a
patient-derived
organoid
biobank
(LICOB)
that
comprehensively
represents
histological
molecular
characteristics
various
types
as
determined
by
multiomics
profiling,
including
genomic,
epigenomic,
transcriptomic,
proteomic
analysis.
Proteogenomic
profiling
LICOB
identified
proliferative
metabolic
subtypes
linked
patient
prognosis.
High-throughput
screening
revealed
distinct
patterns
each
subtype
were
associated
specific
signatures.
Through
analyses
data,
we
responses
predicted
combinations
personalized
treatment.
The
synergistic
inhibition
effect
mTOR
inhibitor
temsirolimus
multitargeted
tyrosine
kinase
lenvatinib
was
validated
in
organoids
xenografts
models.
also
provide
user-friendly
web
portal
help
serve
biomedical
research
community.
Our
study
is
rich
resource
biology
pharmacological
dependencies
may
enable
functional
medicine.
Cell Death and Disease,
Journal Year:
2023,
Volume and Issue:
14(1)
Published: Jan. 9, 2023
Glioblastoma
multiforme
(GBM)
is
the
most
lethal
primary
brain
tumor
with
a
poor
median
survival
of
less
than
15
months.
However,
clinical
strategies
and
effective
therapies
are
limited.
Here,
we
found
that
second-generation
small
molecule
multi-CDK
inhibitor
AT7519
potential
drug
for
GBM
treatment
according
to
high-throughput
screening
via
Approved
Drug
Library
Clinical
Compound
(2718
compounds).
We
significantly
inhibited
cell
viability
proliferation
U87MG,
U251,
patient-derived
cells
in
dose-dependent
manner.
Furthermore,
also
phosphorylation
CDK1/2
arrested
cycle
at
G1-S
G2-M
phases.
More
importantly,
induced
intrinsic
apoptosis
pyroptosis
caspase-3-mediated
cleavage
gasdermin
E
(GSDME).
In
glioblastoma
intracranial
subcutaneous
xenograft
assays,
volume
was
reduced
after
AT7519.
summary,
induces
death
through
multiple
pathways
inhibits
growth,
indicating
chemical
available
treatment.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(2), P. 461 - 461
Published: Jan. 22, 2024
Extensive
research
is
underway
to
develop
new
therapeutic
strategies
counteract
therapy
resistance
in
cancers.
This
review
presents
various
achieve
this
objective.
First,
we
discuss
different
vectorization
platforms
capable
of
releasing
drugs
cancer
cells.
Second,
delve
into
multitarget
therapies
using
drug
combinations
and
dual
anticancer
agents.
section
will
describe
examples
that
have
been
used
treat
solid
tumors.
